LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Randall-Type Monoclonal IgE Kappa Light-Heavy Chain Deposition Disease.

    Isnard, Pierre / Benichou, Nicolas / Sibon, David / Rinsant, Alexia / Goujon, Jean-Michel / Touchard, Guy / Ory, Cécile / Kaaki, Sihem / Colombat, Magali / Do Souto Ferreira, Laura / Avet-Loiseau, Hervé / Karras, Alexandre / Bridoux, Frank / Rabant, Marion

    Kidney international reports

    2023  Volume 8, Issue 7, Page(s) 1464–1468

    Language English
    Publishing date 2023-04-07
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2023.04.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma.

    Lemaitre, Léa / DoSouto Ferreira, Laura / Joubert, Marie-Véronique / Avet-Loiseau, Hervé / Martinet, Ludovic / Corre, Jill / Couderc, Bettina

    International journal of molecular sciences

    2020  Volume 21, Issue 11

    Abstract: Introduction: Multiple myeloma (MM) is a B-cell neoplasm characterized by clonal expansion of malignant plasma cells (MM cells) in the bone-marrow (BM) compartment. BM mesenchymal stromal cells (MSC) from newly diagnosed MM patients were shown to be ... ...

    Abstract Introduction: Multiple myeloma (MM) is a B-cell neoplasm characterized by clonal expansion of malignant plasma cells (MM cells) in the bone-marrow (BM) compartment. BM mesenchymal stromal cells (MSC) from newly diagnosed MM patients were shown to be involved in MM pathogenesis and chemoresistance. The patients displayed a distinct transcriptome and were functionally different from healthy donors' (HD) MSC. Our aim was to determine whether MM-MSC also contributed to relapse.
    Methods: We obtained and characterized patients' MSC samples at diagnosis, two years after intensive treatment, without relapse and at relapse.
    Results: Transcriptomic analysis revealed differences in gene expression between HD and MM-MSC, whatever the stage of the disease. An easier differentiation towards adipogenesis at the expense of osteoblatogeneis was observed, even in patients displaying a complete response to treatment. Although their transcriptome was similar, we found that MSC from relapsed patients had an increased immunosuppressive ability, compared to those from patients in remission.
    Conclusion: We demonstrated that imprinting of MSC transcriptome demonstrated at diagnosis of MM, persisted even after the apparent disappearance of MM cells induced by treatment, suggesting the maintenance of a local context favorable to relapse.
    MeSH term(s) Adipogenesis ; Aged ; Bone Marrow/metabolism ; Bone Marrow Cells/pathology ; Cell Differentiation ; Coculture Techniques ; Drug Resistance, Neoplasm ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Genomic Imprinting ; Humans ; Immunosuppressive Agents/pharmacology ; Leukocytes, Mononuclear/metabolism ; Male ; Mesenchymal Stem Cells/metabolism ; Middle Aged ; Multiple Myeloma/metabolism ; Multiple Myeloma/therapy ; Neoplasm Recurrence, Local ; Principal Component Analysis ; Recurrence ; T-Lymphocytes/cytology ; Transcriptome
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2020-05-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms21113854
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.

    Lemaitre, Léa / Hamaidia, Malik / Descamps, Jean-Gérard / Do Souto Ferreira, Laura / Joubert, Marie-Véronique / Gadelorge, Mélanie / Avet-Loiseau, Hervé / Justo, Arthur / Reina, Nicolas / Deschaseaux, Frederic / Martinet, Ludovic / Bourin, Philippe / Corre, Jill / Espagnolle, Nicolas

    Blood advances

    2021  Volume 6, Issue 2, Page(s) 672–678

    Abstract: Bone marrow (BM) mesenchymal stromal cells (MSCs) are abnormal in multiple myeloma (MM) and play a critical role by promoting growth, survival, and drug resistance of MM cells. We observed higher Toll-like receptor 4 (TLR4) gene expression in MM MSCs ... ...

    Abstract Bone marrow (BM) mesenchymal stromal cells (MSCs) are abnormal in multiple myeloma (MM) and play a critical role by promoting growth, survival, and drug resistance of MM cells. We observed higher Toll-like receptor 4 (TLR4) gene expression in MM MSCs than in MSCs from healthy donors. At the clinical level, we highlighted that TLR4 expression in MM MSCs evolves in parallel with the disease stage. Thus, we reasoned that the TLR4 axis is pivotal in MM by increasing the protumor activity of MSCs. Challenging primary MSCs with TLR4 agonists increased the expression of CD54 and interleukin-6 (IL-6), 2 factors directly implicated in MM MSC-MM cell crosstalk. Then, we evaluated the therapeutic efficacy of a TLR4 antagonist combined or not with conventional treatment in vitro with MSC-MM cell coculture and in vivo with the Vk*MYC mouse model. Selective inhibition of TLR4 specifically reduced the MM MSC ability to support the growth of MM cells in an IL-6-dependent manner and delayed the development of MM in the Vk*MYC mouse model by altering the early disease phase in vivo. For the first time, we demonstrate that specific targeting of the pathological BM microenvironment via TLR4 signaling could be an innovative approach to alter MM pathology development.
    MeSH term(s) Animals ; Cells, Cultured ; Interleukin-6 ; Mesenchymal Stem Cells/metabolism ; Mice ; Multiple Myeloma/metabolism ; Toll-Like Receptor 4/genetics ; Tumor Microenvironment
    Chemical Substances Interleukin-6 ; Toll-Like Receptor 4
    Language English
    Publishing date 2021-10-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2020003704
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.

    Cazaubiel, Titouan / Leleu, Xavier / Perrot, Aurore / Manier, Salomon / Buisson, Laure / Maheo, Sabrina / Do Souto Ferreira, Laura / Lannes, Romain / Pavageau, Luka / Hulin, Cyrille / Marolleau, Jean-Pierre / Voillat, Laurent / Belhadj, Karim / Divoux, Marion / Slama, Borhane / Brechignac, Sabine / Macro, Margaret / Stoppa, Anne-Marie / Sanhes, Laurence /
    Orsini-Piocelle, Frédérique / Fontan, Jean / Chretien, Marie-Lorraine / Demarquette, Hélène / Mohty, Mohamad / Schavgoulidze, Anais / Avet-Loiseau, Herve / Corre, Jill

    Blood

    2022  Volume 139, Issue 17, Page(s) 2666–2672

    Abstract: Primary plasma cell leukemia (pPCL) is an aggressive form of multiple myeloma (MM) that has not benefited from recent therapeutic advances in the field. Because it is very rare and heterogeneous, it remains poorly understood at the molecular level. To ... ...

    Abstract Primary plasma cell leukemia (pPCL) is an aggressive form of multiple myeloma (MM) that has not benefited from recent therapeutic advances in the field. Because it is very rare and heterogeneous, it remains poorly understood at the molecular level. To address this issue, we performed DNA and RNA sequencing of sorted plasma cells from a large cohort of 90 newly diagnosed pPCL and compared with MM. We observed that pPCL presents a specific genomic landscape with a high prevalence of t(11;14) (about half) and high-risk genomic features such as del(17p), gain 1q, and del(1p32). In addition, pPCL displays a specific transcriptome when compared with MM. We then wanted to characterize specifically pPCL with t(11;14). We observed that this subentity displayed significantly fewer adverse cytogenetic abnormalities. This translated into better overall survival when compared with pPCL without t(11;14) (39.2 months vs 17.9 months, P = .002). Finally, pPCL with t(11;14) displayed a specific transcriptome, including differential expression of BCL2 family members. This study is the largest series of patients with pPCL reported so far.
    MeSH term(s) Chromosome Aberrations ; Genomics ; Humans ; Leukemia, Plasma Cell/diagnosis ; Multiple Myeloma/genetics ; Prognosis ; Transcriptome
    Language English
    Publishing date 2022-06-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2021014968
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

    Schavgoulidze, Anaïs / Talbot, Alexis / Perrot, Aurore / Cazaubiel, Titouan / Leleu, Xavier / Manier, Salomon / Buisson, Laure / Mahéo, Sabrina / Do Souto Ferreira, Laura / Pavageau, Luka / Hulin, Cyrille / Marolleau, Jean-Pierre / Voillat, Laurent / Belhadj, Karim / Divoux, Marion / Slama, Borhane / Brechignac, Sabine / Macro, Margaret / Stoppa, Anne-Marie /
    Sanhes, Laurence / Orsini-Piocelle, Frédérique / Fontan, Jean / Chretien, Marie-Lorraine / Demarquette, Hélène / Mohty, Mohamad / Avet-Loiseau, Hervé / Corre, Jill

    Blood

    2022  Volume 141, Issue 11, Page(s) 1308–1315

    Abstract: Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p). ... ...

    Abstract Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p). This study aimed to confirm the adverse effect of 1p32 deletion in patients with newly diagnosed multiple myeloma (NDMM). Among 2551 patients with newly diagnosed multiple myeloma, 11% were harboring del(1p32). Their overall survival (OS) was significantly inferior compared with patients without del(1p32) (median OS: 49 months vs 124 months). Likewise, progression-free survival was significantly shorter. More importantly, biallelic del(1p32) conferred a dramatically poorer prognosis than a monoallelic del(1p32) (median OS: 25 months vs 60 months). As expected, the OS of patients with del(1p32) significantly decreased when this abnormality was associated with other high-risk CAs [del(17p), t(4;14), or gain(1q)]. In the multivariate analysis, del(1p32) appeared as a negative prognostic factor; after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse effect of del(1p32) in multiple myeloma and the relevance of its assessment at diagnosis.
    MeSH term(s) Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/genetics ; Prognosis ; Chromosome Aberrations ; In Situ Hybridization, Fluorescence ; Progression-Free Survival
    Language English
    Publishing date 2022-11-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022017863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top